NeueHealth — Q3 2024 Earnings Presentation
11 slides from NeueHealth's earnings presentation, Nov 7, 2024
Slide 1: NeueHealth Third Quarter 2024 - Earnings Presentation
NeueHealth Third Quarter 2024 - Earnings Presentation November 7, 2024 Privileged & Confidential | © 2024
Slide 2: Disclaimer
Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re
Slide 3: NeueHealth: A Value-Driven Healthcare Company
NeueHealth: A Value-Driven Healthcare Company A value-driven, consumer-centric care model grounded in strong, ongoing relationships with provider and payor partners and proactive consumer engagement NeueHealth Value-driven care delivery and provider enablement business partnering with leading health
Slide 4: Overview of Q3 2024 Results for Continuing Operations
Overview of Q3 2024 Results for Continuing Operations Strong Q3 performance driven by continued solid results in NeueCare and NeueSolutions segments Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) $9.4 Key Considerations • Delivered Q3 ‘24 Revenue of $232
Slide 5: Overview of Year-to-Date 2024 Results for Continuing Operations
Overview of Year-to-Date 2024 Results for Continuing Operations Continued momentum year-to-date demonstrates strength of value-driven care model Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) $17.0 Key Considerations • Revenue of $704.0 million for the n
Slide 6: Balance Sheet and Liquidity Highlights
Balance Sheet and Liquidity Highlights Focused on building a strong foundation for long-term sustainable growth Summary Balance Sheet Q3 ‘24 Key Considerations September 30, December 31, • $242.3 million in total cash and investments, including $123.1 million ($ in thousands) 2024 2023 Assets in reg
Slide 7: Appendix
Appendix
Slide 8: Non-GAAP Reconciliation: Adjusted EBITDA
Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, ($ in thousands) 2024 2023 2024 2023 Net Loss $ (40,365) $ (547,148) $ (102,240) $ (805,236) Loss from discontinued operations 14,358 67,843 42,662 240,321 EBITDA adj
Slide 9: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio
Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, ($ in thousands) 2024 2023 2024 2023 GAAP Operating Cost Ratio 27.5% 26.9% 28.6% 25.5% Impact of share-based and other long- (7.0)% (6.1)% (8.0)% (7.6)%
Slide 10: Forward-Looking Non-GAAP Measures
Forward-Looking Non-GAAP Measures This presentation contains Adjusted EBITDA and Adjusted Operating Cost Ratio, which are non-GAAP financial measures. These non-GAAP financial measures are additions, and not substitutes for or superior to the most directly comparable GAAP financial measures, Net Inc
Slide 11: Slide 11